Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

In Partnership With:

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Cell therapies, most notably CAR T-cell therapies, have had an important impact on the field of hematology, Ramakrishnan says. Most recently, the field has seen pivotal research with CAR T cells in the second-line setting for DLBCL, Ramakrishnan adds.

The phase 3 ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials led to the FDA approvals of axicabtagene ciloleucel (axi-cel; Yescarta) and lisocabtagene maraleucel (liso-cel; Breyanzi) in the second-line setting of DLBCL, Ramakrishnan explains.

Overall, as more treatment options, it is important to consider become available how to sequence these treatments for patients, Ramakrishnan concludes.

Related Videos
View All
Related Content